Information Provided By: 
Fly News Breaks for February 8, 2016
SRPT
Feb 8, 2016 | 09:22 EDT
Piper Jaffray analyst Edward Tenthoff is not surprised that the FDA pushed out the action date for Sarepta's eteplirsen to May 26. The analyst continues to see eteplirsen accelerated approval by the new PDUFA date as a "long shot." A new panel meeting has yet to be scheduled, Tenthoff points out in a research note. He expects the panel discussion to be a plea from the Duchenne muscular dystrophy community and does not think members will be asked to vote on approval. Tenthoff keeps a Neutral rating on Sarepta with a $15 price target.
News For SRPT From the Last 2 Days
There are no results for your query SRPT
